The Research Center of Molecular Biology is the newest scientific subdivision of the institute. Established in 2020, the Center immediately announced itself as a leading provider of the latest methods for treating myocardial infarction, the most dangerous heart disease with a high mortality rate. The Center’s specialists, together with the Ryazan Medical Academy, are conducting a series of experiments on animals to study the impact of the drug developed by the IAMR on the course of myocardial infarction.
The Center’s competence includes studying cellular mechanisms of endocytosis, crucial for studying mechanisms of drug transport inside cells, mitochondrial activity in connection with neurodegenerative diseases and a number of other promising areas.